April 23rd, 2019

Episode #42

Keeping Your Brain Young

Mark and Dr. Gladden invite Dr. Dale Bredesen on the podcast to speak about the science of cognitive decline and its prevention. Dr. Bredesen is an expert on neurodegenerative diseases, and he discusses multiple risk factors for Alzheimer’s and dementia, including those both genetic and environmental. They examine crucial things you should do in your routine and environment to help reduce the risks that contribute to cognitive decline.

Mark and Dr. Gladden review a number of advances in longevity research, considering the impact they might have on improved cognitive function.

Special Guest

Dale E. Bredesen

Dale E. Bredesen, M.D., UCLA and Buck Institute

  • Professor, Department of Molecular and Medical Pharmacology
  • David Geffen School of Medicine at UCLA, Los Angeles, CA
  • Founding President and CEO, Professor Emeritus, Buck Institute for Research on Aging, Novato, CA

Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner. He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging. In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. He and his group developed a new approach to the treatment of Alzheimer’s disease, and this approach led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014, 2016, and 2018. His book, The End of Alzheimer’s, is a New York Times Bestseller.

Visit his website, https://www.ahnphealth.com/dr-bredesen.html

Follow him on Facebook here: https://www.facebook.com/drdalebredesen/